Related Experiment Video
Updated: Jun 21, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Severe community-acquired pneumonia
Marcos I Restrepo1, Antonio Anzueto
1Division of Pulmonary/Critical Care Medicine, South Texas Veterans Health Care System, 7400 Merton Minter Boulevard, San Antonio, TX 78229, USA. restrepom@uthscsa.edu
Abstract:
Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the United States. It accounts for 500,000 hospitalizations and 45,000 deaths each year, and it represents one of the most common causes of ICU admission. The mortality rate due to severe CAP has shown little improvement over the past few years, with rates as high as 58% when patients were admitted to the ICU. Significant interest has focused on the sickest patients who have pneumonia treated in the ICU, regarding identification of need for ICU admission and therapies directed to improve outcomes in patients who have severe CAP. This article reviews epidemiologic, microbiologic, therapeutic, preventive, and outcomes data in patients who have CAP in the ICU.
Related Concept Videos
Pneumonia I: Introduction
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia
Pneumonia III: Complications and Assessment
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia II: Pathophysiology
